HC Wainwright & Co. Maintains Tango Therapeutics (TNGX) Buy Recommendation
Fintel reports that on August 11, 2023, HC Wainwright & Co. maintained coverage of Tango Therapeutics (NASDAQ:TNGX) with a Buy recommendation.
Analyst Price Forecast Suggests 137.06% Upside
As of August 2, 2023, the average one-year price target for Tango Therapeutics is 15.50. The forecasts range from a low of 11.11 to a high of $18.90. The average price target represents an increase of 137.06% from its latest reported closing price of 6.54.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Tango Therapeutics is 27MM, a decrease of 20.04%. The projected annual non-GAAP EPS is -1.64.
What is the Fund Sentiment?
There are 206 funds or institutions reporting positions in Tango Therapeutics. This is an increase of 4 owner(s) or 1.98% in the last quarter. Average portfolio weight of all funds dedicated to TNGX is 0.30%, a decrease of 19.33%. Total shares owned by institutions increased in the last three months by 1.52% to 70,547K shares.
What are Other Shareholders Doing?
Trv Gp Iv holds 19,364K shares representing 21.89% ownership of the company. No change in the last quarter.
Boxer Capital holds 7,124K shares representing 8.05% ownership of the company. No change in the last quarter.
Southpoint Capital Advisors holds 4,500K shares representing 5.09% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 4,201K shares representing 4.75% ownership of the company. No change in the last quarter.
Cormorant Asset Management holds 4,117K shares representing 4.65% ownership of the company. No change in the last quarter.
Tango Therapeutics Background Information
(This description is provided by the company.)
Tango Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops drugs and medicines for the treatment of patients. Tango Therapeutics serves customers in the State of Massachusetts.
Additional reading:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Summarize this content to 100 words
Fintel reports that on August 11, 2023, HC Wainwright & Co. maintained coverage of Tango Therapeutics (NASDAQ:TNGX) with a Buy recommendation. Analyst Price Forecast Suggests 137.06% Upside As of August 2, 2023, the average one-year price target for Tango Therapeutics is 15.50. The forecasts range from a low of 11.11 to a high of $18.90. The average price target represents an increase of 137.06% from its latest reported closing price of 6.54.
See our leaderboard of companies with the largest price target upside. The projected annual revenue for Tango Therapeutics is 27MM, a decrease of 20.04%. The projected annual non-GAAP EPS is -1.64. What is the Fund Sentiment? There are 206 funds or institutions reporting positions in Tango Therapeutics. This is an increase of 4 owner(s) or 1.98% in the last quarter. Average portfolio weight of all funds dedicated to TNGX is 0.30%, a decrease of 19.33%. Total shares owned by institutions increased in the last three months by 1.52% to 70,547K shares. What are Other Shareholders Doing? Trv Gp Iv holds 19,364K shares representing 21.89% ownership of the company. No change in the last quarter. Boxer Capital holds 7,124K shares representing 8.05% ownership of the company. No change in the last quarter.
Southpoint Capital Advisors holds 4,500K shares representing 5.09% ownership of the company. No change in the last quarter. EcoR1 Capital holds 4,201K shares representing 4.75% ownership of the company. No change in the last quarter. Cormorant Asset Management holds 4,117K shares representing 4.65% ownership of the company. No change in the last quarter. Tango Therapeutics Background Information(This description is provided by the company.) Tango Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops drugs and medicines for the treatment of patients. Tango Therapeutics serves customers in the State of Massachusetts.
Additional reading: This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
https://www.nasdaq.com/articles/hc-wainwright-co.-maintains-tango-therapeutics-tngx-buy-recommendation HC Wainwright & Co. Maintains Tango Therapeutics (TNGX) Buy Recommendation